Cite
HARVARD Citation
Furman, R. et al. (2017). Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenström's macroglobulinemia. Leukemia & lymphoma. 58 (6), pp. 1502-1505. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Furman, R. et al. (2017). Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenström's macroglobulinemia. Leukemia & lymphoma. 58 (6), pp. 1502-1505. [Online].